Accessibility StatementSkip Navigation TEL AVIV, Israel, Nov. 26, 2025 /PRNewswire/ —Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic, and gastrointestinal oncology indications, reports financial results for the three and nine months ended September 30, 2025 and recent developments. Financial Summary – Third Quarter 2025 vs. Third Quarter 2024 Recent Business Updates About Galmed Pharmaceuticals Ltd. We are a ...